Analysis of Clinical Progress of Elpiscience's Core Product ES102

According to the latest information [1], Elpiscience’s core product ES102 is a hexavalent antibody targeting and activating OX40 with a “first-in-class” design concept, and its clinical development progress is leading in the industry.

The unique design of ES102 enables it to potently activate the OX40 pathway without exogenous cross-linking. Compared with traditional bivalent or tetravalent OX40 antibodies, ES102 has stronger immune activation ability. Preclinical studies have shown significant anti-tumor efficacy both as a monotherapy and in combination with immune checkpoint inhibitors PD-1/PD-L1, along with favorable safety profiles [2].

• ES102 first entered clinical stages in the United States in 2019 [1]
• Elpiscience has completed two Phase 1 clinical trials of ES102 in China for patients with advanced solid tumors, including monotherapy and combination with PD-1 checkpoint inhibitors [3]

• In January 2024, Elpiscience initiated a Phase 2 clinical trial in China for ES102 combined with Toripalimab in patients with advanced non-small cell lung cancer (NSCLC) [3]
• It has entered into a clinical cooperation agreement with Junshi Biosciences to jointly evaluate the safety and preliminary efficacy of ES102 as monotherapy and in combination with Toripalimab in cancer treatment [1]

In clinical trials, ES102 has demonstrated favorable safety and anti-tumor activity:

• Combined with PD-1 antibodies in NSCLC patients resistant to PD-1 checkpoint inhibitors [3]
• Combined with PD-1 antibodies in esophageal squamous cell carcinoma (ESCC) patients resistant to PD-1 checkpoint inhibitors [3]

According to data from CIC Consulting, as of the last practicable date, no OX40 agonist has been approved globally, and ES102 is one of only two OX40 agonist candidates in clinical development at Phase 2 or later stages worldwide. This indicates that ES102 is in the first tier in the global OX40 agonist R&D field [3].

Elpiscience stated in its prospectus that based on regulatory communications and marketing approval, it expects to commercialize its clinical-stage assets as early as 2028 [3].

As Elpiscience’s core product, ES102 has a differentiated advantage with its hexavalent OX40 agonist design. It has completed Phase 1 clinical trials and entered Phase 2 development. Focusing on the unmet medical need of treating cancer patients with poor response to immune checkpoint inhibitors (ICI) reflects Elpiscience’s innovative layout in the field of cancer immunotherapy.

---

[1] Elpiscience’s ES102 Approved for Clinical Trials (https://cn.elpiscience.com/new/kewangyiyaoes102huopijinrulinchuangshiyan.html)
[2] Elpiscience Official Website (https://cn.elpiscience.com/getJob.php)
[3] Three-Year Cumulative Loss of 1.7 Billion Yuan, Founder Earns 10 Million Annual Salary, Elpiscience Resubmits Listing Application to HKEX (https://stcn.com/article/detail/1846539.html)